Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tatos Akopian

Co-Author

This page shows the publications co-authored by Tatos Akopian and Alfred Goldberg.
Connection Strength

2.283
  1. Cleavage Specificity of Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates and Boronate Inhibitors with Anti-bacterial Activity. J Biol Chem. 2015 Apr 24; 290(17):11008-20.
    View in: PubMed
    Score: 0.650
  2. The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring. EMBO J. 2012 Mar 21; 31(6):1529-41.
    View in: PubMed
    Score: 0.523
  3. Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis. Anal Biochem. 2019 02 15; 567:30-37.
    View in: PubMed
    Score: 0.211
  4. Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum. J Biol Chem. 1997 Jan 17; 272(3):1791-8.
    View in: PubMed
    Score: 0.185
  5. Structure and Functional Properties of the Active Form of the Proteolytic Complex, ClpP1P2, from Mycobacterium tuberculosis. J Biol Chem. 2016 Apr 01; 291(14):7465-76.
    View in: PubMed
    Score: 0.173
  6. Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J Biol Chem. 2001 Sep 28; 276(39):36474-81.
    View in: PubMed
    Score: 0.063
  7. ClpX Is Essential and Activated by Single-Strand DNA Binding Protein in Mycobacteria. J Bacteriol. 2021 Jan 25; 203(4).
    View in: PubMed
    Score: 0.061
  8. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell. 1999 Sep; 4(3):395-402.
    View in: PubMed
    Score: 0.055
  9. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem. 1999 Feb 05; 274(6):3363-71.
    View in: PubMed
    Score: 0.053
  10. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J Biol Chem. 1998 Jan 23; 273(4):1982-9.
    View in: PubMed
    Score: 0.050
  11. New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem. 1997 Mar-Apr; 378(3-4):131-40.
    View in: PubMed
    Score: 0.047
  12. Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Mol Biol Rep. 1997 Mar; 24(1-2):69-75.
    View in: PubMed
    Score: 0.047
  13. Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease. Mol Microbiol. 2016 07; 101(2):194-209.
    View in: PubMed
    Score: 0.044
  14. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2015 Feb; 59(2):880-9.
    View in: PubMed
    Score: 0.040
  15. Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol. 2014 Apr 24; 21(4):509-518.
    View in: PubMed
    Score: 0.038
  16. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog. 2012 Feb; 8(2):e1002511.
    View in: PubMed
    Score: 0.033
  17. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. 1997 May 16; 272(20):13437-45.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.